BR9711228A - Método para a inibição da expressão de fas - Google Patents

Método para a inibição da expressão de fas

Info

Publication number
BR9711228A
BR9711228A BR9711228-3A BR9711228A BR9711228A BR 9711228 A BR9711228 A BR 9711228A BR 9711228 A BR9711228 A BR 9711228A BR 9711228 A BR9711228 A BR 9711228A
Authority
BR
Brazil
Prior art keywords
fas
expression
inhibiting
adrenoceptor
inhibition
Prior art date
Application number
BR9711228-3A
Other languages
English (en)
Inventor
Giora Zeev Feuerstein
Tian-Li Yue
Original Assignee
Boeringer Mannheim Pharmaceuti
Smithkline Beckman Corp Limite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boeringer Mannheim Pharmaceuti, Smithkline Beckman Corp Limite filed Critical Boeringer Mannheim Pharmaceuti
Publication of BR9711228A publication Critical patent/BR9711228A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODO PARA A INIBIçãO DA EXPRESSãO DE FAS" A presente invenção fornece uma metologia para a inibição da expressão de Fas que compreende a administração, em um mamífero, precisando para isso de uma quantidade eficaz, de um composto que é um antagonista dual não-seletivo de <225>-adrenoceptor e <244>~ 1~-adrenoceptor.
BR9711228-3A 1996-08-23 1997-08-22 Método para a inibição da expressão de fas BR9711228A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2448696P 1996-08-23 1996-08-23
PCT/US1997/014792 WO1998007321A1 (en) 1996-08-23 1997-08-22 Method for inhibiting the expression of fas

Publications (1)

Publication Number Publication Date
BR9711228A true BR9711228A (pt) 2000-01-11

Family

ID=21820837

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711228-3A BR9711228A (pt) 1996-08-23 1997-08-22 Método para a inibição da expressão de fas

Country Status (17)

Country Link
US (1) US6096777A (pt)
EP (1) EP0924985A4 (pt)
JP (1) JP2001504804A (pt)
KR (1) KR20000068322A (pt)
CN (1) CN1233150A (pt)
AU (1) AU4083097A (pt)
BR (1) BR9711228A (pt)
CA (1) CA2264178A1 (pt)
CZ (1) CZ59199A3 (pt)
HU (1) HUP9904243A3 (pt)
IL (1) IL128613A (pt)
NO (1) NO990792L (pt)
NZ (1) NZ334307A (pt)
PL (1) PL331766A1 (pt)
TR (1) TR199900370T2 (pt)
WO (1) WO1998007321A1 (pt)
ZA (1) ZA977565B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
US7268156B2 (en) * 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
WO2004024145A1 (en) * 2002-09-10 2004-03-25 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
CA2547137A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
WO2007042912A2 (en) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation

Also Published As

Publication number Publication date
EP0924985A4 (en) 2000-12-06
ZA977565B (en) 1999-02-17
IL128613A (en) 2004-07-25
WO1998007321A1 (en) 1998-02-26
NO990792L (no) 1999-04-15
CA2264178A1 (en) 1998-02-26
US6096777A (en) 2000-08-01
PL331766A1 (en) 1999-08-02
TR199900370T2 (xx) 1999-05-21
HUP9904243A3 (en) 2001-09-28
JP2001504804A (ja) 2001-04-10
HUP9904243A2 (hu) 2000-05-28
AU4083097A (en) 1998-03-06
CZ59199A3 (cs) 1999-08-11
IL128613A0 (en) 2000-01-31
EP0924985A1 (en) 1999-06-30
NO990792D0 (no) 1999-02-19
KR20000068322A (ko) 2000-11-25
CN1233150A (zh) 1999-10-27
NZ334307A (en) 2000-11-24

Similar Documents

Publication Publication Date Title
BR9711228A (pt) Método para a inibição da expressão de fas
BR9908857A (pt) Métodos e composições para tratamento, inibição e prevenção de mucosite
DK1091745T3 (da) Behandling af hyperproliferative forstyrrelser
MY125602A (en) Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
BR0109966A (pt) Combinação de compostos orgânicos
BR0114758A (pt) Inibidores do receptor ep4 para tratamento de artrite reumatóide
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
ATE291429T1 (de) Mittel gegen juckreiz
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
BR9916518A (pt) Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
ATE283050T1 (de) Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie
DE69715511D1 (de) Kopieverhinderungssystem für Multimediaeinrichtung
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
PT817625E (pt) Composicoes para o tratamento de pele fotodanificada, compreendendo um antagonista de rar-alfa e um retinoide multi-selectivo
GB9804886D0 (en) Therapeutic combination
BR9809848A (pt) Composição
BR9710957A (pt) Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico
BR0214643A (pt) Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI